Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, Postema R, Townsend R, Roudaut M (2015) The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus. Diab Med 32(7):890–898

Article  CAS  Google Scholar 

Chatterjee SMD, Khunti K, Davies MJ (2017) Type 2 diabetes. Lancet 389(10085):2239–2251

Article  CAS  PubMed  Google Scholar 

Dahal PK, Rawal LB, Mahumud RA, Paudel G, Sugishita T, Vandelanotte C (2022) Economic evaluation of health behavior interventions to prevent and manage type 2 diabetes mellitus in asia: a systematic review of randomized controlled trials. Int J Environ Res Public Health 19(17):10799

Article  CAS  PubMed  PubMed Central  Google Scholar 

Díaz de León-Castañeda C, Altagracia-Martínez M, Kravzov-Jinich J, Cárdenas-Elizalde MR, Moreno-Bonett C, Martínez-Núñez JM (2012) Cost-effectiveness study of oral hypoglycemic agents in the treatment of outpatients with type 2 diabetes attending a public primary care clinic in Mexico City. Clinicoecon Outcomes Res 4:57–65

PubMed  Google Scholar 

Edney LC, Haji Ali Afzali H, Cheng TC, Karnon JC (2017) Estimating the Reference incremental cost-effectiveness ratio for the Australian health system. Pharmacoeconomics 36(2):239–252

Article  Google Scholar 

Einarson TR, Acs A, Ludwig C, Panton UH (2018) Economic burden of cardiovascular disease in type 2 diabetes: a systematic review. Value Health 21(7):881–890

Article  PubMed  Google Scholar 

El Alili M, van Dongen JM, Goldfeld KS, Heymans MW, van Tulder MW, Bosmans JE (2020) Taking the analysis of trial-based economic evaluations to the next level: the importance of accounting for clustering. Pharmacoeconomics 38(11):1247–1261

Article  PubMed  PubMed Central  Google Scholar 

Evans M, Mehta R, Gundgaard J, Chubb B (2018) Cost-Effectiveness of insulin Degludec vs Insulin Glargine U100 in type 1 and type 2 diabetes mellitus in a UK setting. Diab Ther 9(5):1919–1930

Article  Google Scholar 

Han G, Hu S, Zhang X, Qiu Z, Huang Z (2022) Insulin degludec/liraglutide versus its monotherapy on T2D patients: a lifetime cost-utility analysis in China. Front Pharmacol 13:1011624

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hollenbeak CS, Boltz MM, Wang L, Schubart J, Ortenzi G, Zhu J, Dillon PW (2011) Cost-effectiveness of the national surgical quality improvement program. Ann Surg 254(4):619–624

Article  PubMed  Google Scholar 

Hunt B, Mocarski M, Valentine WJ, Langer J (2017) IDegLira versus insulin Glargine U100: a long-term cost-effectiveness analysis in the US setting. Diab Ther Res Treat Educ Diab Relat Disord 8(3):531–544

CAS  Google Scholar 

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S (2022) Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ 376:e067975

Article  PubMed  PubMed Central  Google Scholar 

McEwan P, Bennett H, Khunti K, Wilding J, Edmonds C, Thuresson M, Wittbrodt E, Fenici P, Kosiborod M (2020) Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence. Diab Obes Metab 22(12):2364–2374

Article  CAS  Google Scholar 

Mezquita Raya P, Peŕrez A, Ramiŕez de Arellano A, Briones T, Hunt B, Valentine WJ (2013) Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin. Diab Ther Res Treat Educ Diab Relat Disord 4(2):417–430

Google Scholar 

Nguyen E, Coleman CI, Nair S, Weeda ER (2018) Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk. J Diab Complicat 32(2):210–215

Article  Google Scholar 

Pérez A, Mezquita Raya P, Ramiŕez de Arellano A, Briones T, Hunt B, Valentine WJ (2015) Cost-effectiveness analysis of incretin therapy for type 2 diabetes in Spain: 1.8 mg Liraglutide versus Sitagliptin. Diabetes Ther 6(1):61–74

Article  PubMed  PubMed Central  Google Scholar 

Petrou S, Gray A (2011) Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. BMJ 342(7806):67–1073

Google Scholar 

Pham MT, Rajić A, Greig JD, Sargeant JM, Papadopoulos A, McEwen SA (2014) A scoping review of scoping reviews: advancing the approach and enhancing the consistency. Res Syn Meth 5(4):371–385

Article  Google Scholar 

Ramos M, Cummings MH, Ustyugova A, Raza SI, de Silva SU, Lamotte M (2020) Long-Term cost-effectiveness analyses of Empagliflozin versus oral Semaglutide, in Addition to Metformin, for the treatment of type 2 diabetes in the UK. Diab Ther 11(9):2041–2055

Article  CAS  Google Scholar 

Rojas G, Nunes A (2021) Pharmacoeconomic analysis of Sitagliptin/Metformin for the treatment of type 2 diabetes Mellitus: a cost-effectiveness study. Value Health Reg Issues 26:33–39

Article  PubMed  Google Scholar 

Sculpher MJ, Claxton K, Drummond M, McCabe C (2006) Whither trial-based economic evaluation for health care decision making? Health Econ 15(7):677–687

Article  PubMed  Google Scholar 

Seuring T, Archangelidi O, Suhrcke M (2015) The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics 33(8):811–831

Article  PubMed  PubMed Central  Google Scholar 

Smith-Palmer J, Fajardo-Montañana C, Pollock RF, Ericsson A, Valentine WJ (2012) Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. J Med Econ 15(5):977–986

Article  CAS  PubMed  Google Scholar 

Sun X, Guo L, Shang H, Ren M, Wang Y, Huo D, Lei X, Wang H, Zhai J (2015) The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design. Trials [Electronic Resource] 16:496

PubMed  Google Scholar 

Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Özge T, Straus SE (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169(7):467–473

Article  PubMed  Google Scholar 

Van Haalen HGM, Pompen M, Bergenheim K, McEwan P, Townsend R, Roudaut M (2014) Cost effectiveness of adding Dapagliflozin to insulin for the treatment of type 2 diabetes Mellitus in the Netherlands. Clin Drug Investig 34(2):135–146

Article  CAS  PubMed  Google Scholar 

Wang B, Roth JA, Nguyen H, Felber E, Furnback W, Garrison LP (2015) The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States. PLoS ONE [Electronic Resource] 10(4):e0121915

Article  PubMed  Google Scholar